311 related articles for article (PubMed ID: 31722192)
1. Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing.
Garcia B; Lee J; Edraki A; Hidalgo-Reyes Y; Erwood S; Mir A; Trost CN; Seroussi U; Stanley SY; Cohn RD; Claycomb JM; Sontheimer EJ; Maxwell KL; Davidson AR
Cell Rep; 2019 Nov; 29(7):1739-1746.e5. PubMed ID: 31722192
[TBL] [Abstract][Full Text] [Related]
2. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
[TBL] [Abstract][Full Text] [Related]
3. AcrIIA5 Inhibits a Broad Range of Cas9 Orthologs by Preventing DNA Target Cleavage.
Song G; Zhang F; Zhang X; Gao X; Zhu X; Fan D; Tian Y
Cell Rep; 2019 Nov; 29(9):2579-2589.e4. PubMed ID: 31775029
[TBL] [Abstract][Full Text] [Related]
4. Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein.
Hoffmann MD; Mathony J; Upmeier Zu Belzen J; Harteveld Z; Aschenbrenner S; Stengl C; Grimm D; Correia BE; Eils R; Niopek D
Nucleic Acids Res; 2021 Mar; 49(5):e29. PubMed ID: 33330940
[TBL] [Abstract][Full Text] [Related]
5. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
7. Development of aptamer-based inhibitors for CRISPR/Cas system.
Zhao J; Inomata R; Kato Y; Miyagishi M
Nucleic Acids Res; 2021 Feb; 49(3):1330-1344. PubMed ID: 33123724
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic disorder is essential for Cas9 inhibition of anti-CRISPR AcrIIA5.
An SY; Ka D; Kim I; Kim EH; Kim NK; Bae E; Suh JY
Nucleic Acids Res; 2020 Jul; 48(13):7584-7594. PubMed ID: 32544231
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CRISPR-Cas9 ribonucleoprotein complex assembly by anti-CRISPR AcrIIC2.
Thavalingam A; Cheng Z; Garcia B; Huang X; Shah M; Sun W; Wang M; Harrington L; Hwang S; Hidalgo-Reyes Y; Sontheimer EJ; Doudna J; Davidson AR; Moraes TF; Wang Y; Maxwell KL
Nat Commun; 2019 Jun; 10(1):2806. PubMed ID: 31243272
[TBL] [Abstract][Full Text] [Related]
10. Coupling Cas9 to artificial inhibitory domains enhances CRISPR-Cas9 target specificity.
Aschenbrenner S; Kallenberger SM; Hoffmann MD; Huck A; Eils R; Niopek D
Sci Adv; 2020 Feb; 6(6):eaay0187. PubMed ID: 32076642
[TBL] [Abstract][Full Text] [Related]
11. Naturally Occurring Off-Switches for CRISPR-Cas9.
Pawluk A; Amrani N; Zhang Y; Garcia B; Hidalgo-Reyes Y; Lee J; Edraki A; Shah M; Sontheimer EJ; Maxwell KL; Davidson AR
Cell; 2016 Dec; 167(7):1829-1838.e9. PubMed ID: 27984730
[TBL] [Abstract][Full Text] [Related]
12. Manipulating plant RNA-silencing pathways to improve the gene editing efficiency of CRISPR/Cas9 systems.
Mao Y; Yang X; Zhou Y; Zhang Z; Botella JR; Zhu JK
Genome Biol; 2018 Sep; 19(1):149. PubMed ID: 30266091
[TBL] [Abstract][Full Text] [Related]
13. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
15. Allosteric inhibition of CRISPR-Cas9 by bacteriophage-derived peptides.
Cui YR; Wang SJ; Chen J; Li J; Chen W; Wang S; Meng B; Zhu W; Zhang Z; Yang B; Jiang B; Yang G; Ma P; Liu J
Genome Biol; 2020 Feb; 21(1):51. PubMed ID: 32102684
[TBL] [Abstract][Full Text] [Related]
16. Potent CRISPR-Cas9 inhibitors from
Watters KE; Shivram H; Fellmann C; Lew RJ; McMahon B; Doudna JA
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6531-6539. PubMed ID: 32156733
[TBL] [Abstract][Full Text] [Related]
17. A glance at genome editing with CRISPR-Cas9 technology.
Barman A; Deb B; Chakraborty S
Curr Genet; 2020 Jun; 66(3):447-462. PubMed ID: 31691023
[TBL] [Abstract][Full Text] [Related]
18. A Genome-Editing Nanomachine Constructed with a Clustered Regularly Interspaced Short Palindromic Repeats System and Activated by Near-Infrared Illumination.
Peng H; Le C; Wu J; Li XF; Zhang H; Le XC
ACS Nano; 2020 Mar; 14(3):2817-2826. PubMed ID: 32048826
[TBL] [Abstract][Full Text] [Related]
19. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
Cai W; Luo T; Mao L; Wang M
Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
[TBL] [Abstract][Full Text] [Related]
20. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type IIC Anti-CRISPR Proteins.
Zhu Y; Gao A; Zhan Q; Wang Y; Feng H; Liu S; Gao G; Serganov A; Gao P
Mol Cell; 2019 Apr; 74(2):296-309.e7. PubMed ID: 30850331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
